Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer - GeparQuinto

Next Previous
X
Search
Trial Profile

A Phase III Trials Program Exploring the Integration of Bevacizumab, Everolimus (RAD001), and Lapatinib Into Current Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer - GeparQuinto

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Everolimus (Primary) ; Lapatinib (Primary) ; Cyclophosphamide; Docetaxel; Epirubicin; Paclitaxel; Trastuzumab
  • Indications Early breast cancer; HER2 negative breast cancer; HER2 positive breast cancer; Triple negative breast cancer
  • Focus Adverse reactions; Biomarker; Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms GeparQuinto

    • Most Recent Events

    • 23 May 2018 Results (n=2600) assessing the effects of BRCA1/2 mutations on pathologic complete response (pCR) and disease-free survival (DFS) in a cohort of patients with TNBC treated with anthracycline and taxane-containing chemotherapy, with or without bevacizumab, were published in the Journal of Clinical Oncology.
    • 15 Mar 2018 Primary endpoint (To compare the pCR rates of neoadjuvant treatment in Setting III) has not been met as per the results published in the Journal of Clinical Oncology.
    • 15 Mar 2018 Results (n=620) assessing long term outcomes in patients with HER2-positive tumors published in the Journal of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top